This paperl focuses on issues relating to reliable detection and predictive analyses of HER-2 and topo IIa, and highlights potential developments in improving individualized approach to anthracycline use in early breast cancer patients.
The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients / Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - ELETTRONICO. - (2009), pp. 662-667.